Text Size

Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01193257
First received: August 31, 2010
Last updated: January 23, 2013
Last verified: January 2013
History of Changes
  Purpose

This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel plus prednisone compared with placebo plus prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) that has progressed following Docetaxel-based therapy


Condition Intervention Phase
Prostate Cancer
 Drug: Orteronel + prednisone
Drug: Placebo + prednisone
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or Following Docetaxel-based Therapy

Resource links provided by NLM:

Drug Information available for: Prednisone
U.S. FDA Resources

Further study details as provided by Millennium Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Overall survival (OS) [ Time Frame: Time from patient randomization to death from any cause ] [ Designated as safety issue: No ]
    Patients will be followed for survival until 80% of patients have died or are lost to follow-up


Secondary Outcome Measures:
  • 50% prostate specific antigen (PSA) response at 12 weeks [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Pain response at 12 weeks [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Radiographic progression-free survival (rPFS) [ Time Frame: Time from patient randomization to radiographic disease progression or death from any cause, whichever occurs first ] [ Designated as safety issue: No ]

Estimated Enrollment: 1083
Study Start Date: November 2010
Estimated Study Completion Date: July 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Orteronel + prednisone Drug: Orteronel + prednisone
Orteronel and prednisone will be administered orally twice a day continuously throughout the study until disease progression is documented
Other Name: TAK-700
Placebo Comparator: Placebo + prednisone Drug: Placebo + prednisone
Placebo and prednisone will be administered orally twice a day continuously throughout the study until disease progression is documented

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Each patient must meet all of the following inclusion criteria:

  • Voluntary written consent
  • Male patients 18 years or older
  • Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma
  • Radiograph-documented metastatic disease
  • Progressive disease
  • Prior surgical castration or concurrent use of an agent for medical castration
  • Have progressive disease during or following 1 or 2 regimens of cytotoxic chemotherapy, 1 of which must have included docetaxel. Must have received ≥ 360 mg/m2 of docetaxel within a 6-month period. Patients who were clearly intolerant to docetaxel or develop progressive disease before receiving ≥ 360 mg/m2 are also eligible if they have received at least 225 mg/m2 of docetaxel within a 6-month period and meet the other study entry criteria.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
  • Even if surgically sterilized, patients must Practice effective barrier contraception during the entire study treatment period and for 4 months after the last dose of study drug, OR Abstain from heterosexual intercourse
  • Meet screening laboratory values as specified in protocol
  • Stable medical condition
  • Life expectancy of 6 months or more
  • Patients who have had up to 2 prior chemotherapy treatments are eligible to participate

Exclusion Criteria:

Patients meeting any of the following exclusion criteria are not to be enrolled in the study:

  • Known hypersensitivity to orteronel, prednisone or gonadotropin-releasing hormone (GnRH) analogue
  • Received prior therapy with orteronel, aminoglutethimide, ketoconazole or abiraterone
  • Any other therapies for prostate cancer, except for GnRH analogue therapy, must be discontinued 2 weeks before the first dose of study drug
  • Radioisotope therapy or external beam radiation therapy within 4 weeks of first dose of study drug
  • Documented central nervous system metastases
  • Treatment with any investigational compound within 30 days prior ro first dose of study drug (Patients who are in long-term follow-up following active treatment in other trials are eligible)
  • Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected
  • Uncontrolled cardiovascular condition as specified in study protocol
  • Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
  • Unwilling or unable to comply with protocol
  • Known gastrointestinal disease or procedure that could interfere with oral absorption or tolerance of orteronel
  • Uncontrolled nausea, vomiting, or diarrhea despite appropriate medical therapy
  • Patients whose prostate cancer is confined to just the prostrate bed or immediate adjacent tissue
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01193257

  Show 79 Study Locations
Sponsors and Collaborators
Millennium Pharmaceuticals, Inc.
Investigators
Study Director: Medical Monitor Millennium Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01193257     History of Changes
Other Study ID Numbers: C21005, 2010-018662-23
Study First Received: August 31, 2010
Last Updated: January 23, 2013
Health Authority: United States: Food and Drug Administration
European Union: European Medicines Agency

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Prednisone
Glucocorticoids
 Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Therapeutic Uses
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on May 21, 2013